These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20237179)

  • 1. Biodegradable sirolimus-loaded poly(lactide) nanoparticles as drug delivery system for the prevention of in-stent restenosis in coronary stent application.
    Luderer F; Löbler M; Rohm HW; Gocke C; Kunna K; Köck K; Kroemer HK; Weitschies W; Schmitz KP; Sternberg K
    J Biomater Appl; 2011 May; 25(8):851-75. PubMed ID: 20237179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug loaded nanoparticle coating on totally bioresorbable PLLA stents to prevent in-stent restenosis.
    Zhao J; Mo Z; Guo F; Shi D; Han QQ; Liu Q
    J Biomed Mater Res B Appl Biomater; 2018 Jan; 106(1):88-95. PubMed ID: 27875036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
    Koppara T; Joner M; Bayer G; Steigerwald K; Diener T; Wittchow E
    Thromb Haemost; 2012 Jun; 107(6):1161-71. PubMed ID: 22535188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
    Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
    Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secreted Matrix Metalloproteinase-9 of Proliferating Smooth Muscle Cells as a Trigger for Drug Release from Stent Surface Polymers in Coronary Arteries.
    Gliesche DG; Hussner J; Witzigmann D; Porta F; Glatter T; Schmidt A; Huwyler J; Meyer Zu Schwabedissen HE
    Mol Pharm; 2016 Jul; 13(7):2290-300. PubMed ID: 27241028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis.
    Zago AC; Raudales JC; Attizzani G; Matte BS; Yamamoto GI; Balvedi JA; Nascimento L; Kosachenco BG; Centeno PR; Zago AJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):E124-9. PubMed ID: 22566402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of interfacial layer wettability and thickness on the coating morphology and sirolimus release for drug-eluting stent.
    Bedair TM; Yu SJ; Im SG; Park BJ; Joung YK; Han DK
    J Colloid Interface Sci; 2015 Dec; 460():189-99. PubMed ID: 26319336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis.
    Zamani M; Prabhakaran MP; Varshosaz J; Mhaisalkar PS; Ramakrishna S
    Acta Biomater; 2016 Sep; 42():316-328. PubMed ID: 27397493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent.
    Vogt F; Stein A; Rettemeier G; Krott N; Hoffmann R; vom Dahl J; Bosserhoff AK; Michaeli W; Hanrath P; Weber C; Blindt R
    Eur Heart J; 2004 Aug; 25(15):1330-40. PubMed ID: 15288161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.
    Clever YP; Cremers B; Krauss B; Böhm M; Speck U; Laufs U; Scheller B
    EuroIntervention; 2011 May; 7 Suppl K():K32-42. PubMed ID: 22027725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New stent surface materials: the impact of polymer-dependent interactions of human endothelial cells, smooth muscle cells, and platelets.
    Busch R; Strohbach A; Rethfeldt S; Walz S; Busch M; Petersen S; Felix S; Sternberg K
    Acta Biomater; 2014 Feb; 10(2):688-700. PubMed ID: 24148751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles.
    Zou W; Cao G; Xi Y; Zhang N
    Drug Deliv; 2009 Jan; 16(1):15-23. PubMed ID: 19555304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and characterization of letrozole-loaded poly(d,l-lactide) nanoparticles for drug delivery in breast cancer therapy.
    Alemrayat B; Elhissi A; Younes HM
    Pharm Dev Technol; 2019 Feb; 24(2):235-242. PubMed ID: 29561210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro study of drug-eluting stent coatings based on poly(L-lactide) incorporating cyclosporine A - drug release, polymer degradation and mechanical integrity.
    Sternberg K; Kramer S; Nischan C; Grabow N; Langer T; Hennighausen G; Schmitz KP
    J Mater Sci Mater Med; 2007 Jul; 18(7):1423-32. PubMed ID: 17387586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus-eluting stents for the prevention of restenosis in a worst-case scenario of diffuse and recurrent in-stent restenosis.
    Werner GS; Emig U; Krack A; Schwarz G; Figulla HR
    Catheter Cardiovasc Interv; 2004 Nov; 63(3):259-64. PubMed ID: 15505841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries.
    Banai S; Chorny M; Gertz SD; Fishbein I; Gao J; Perez L; Lazarovichi G; Gazit A; Levitzki A; Golomb G
    Biomaterials; 2005 Feb; 26(4):451-61. PubMed ID: 15275819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease.
    Grube E; Buellesfeld L
    Expert Rev Med Devices; 2006 Nov; 3(6):731-41. PubMed ID: 17280537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.